"Panacea Biotec... has received awards worth USD 24.32 million from U N agencies (Unicef and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified wP-based Pentavalent vaccine (DTwPHepB-Hib)," the company said in a filing to BSE.
"UNICEF award is for calendar year 2020 and award of PAHO is for three calendar years i.e. 2020-2022," company said in its BSE filing.
The four formulations are Vildagliptin 50 mg, Vildagliptin 50 mg + Metformin HCL 500 mg, Vildagliptin 50 mg + Metformin HCL 850 mg and Vildagliptin 50 mg + Metformin HCL 1,000 mg, Panacea Biotec said in a filing to the BSE.
At 0924 hrs, Panacea Biotec was quoting Rs 207.55, up 14.57 percent on the BSE.
The joint venture fund has been active in the pharma business and the announcement comes after the February 26 announcement by Panacea about reaching a one-time settlement with the lenders to pay off Rs 864 crore of debt.
Panacea will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the US.
As part of the settlement agreement, Panacea and Apotex will receive a non-exclusive license under which Panacea Biotec may begin selling generic version of Abraxane in the US.
The company's Baddi facility manufactures anti-cancer injectables and oral solid dosage formulations.
The company's abbreviated new drug application (ANDA) for Paclitaxel Protein bound particles for injectable suspension, 100mg/vial has been accepted for filing by the US Food and Drug Administration (USFDA), Panacea Biotec said in a BSE filing.
The company is also entitled for 180 days of shared market exclusivity for the Prasugrel HCL tablets, it added.
Panacea's Prasugrel copies are first-to-file abbreviated new drug applications (ANDAs) approved by US FDA - making eligible for 180-days of shared marketing exclusivity under the provisions of Hatch-Waxman Act.
Prasugrel is currently having annual sales of approximately USD 600 million in USA.
Under a memorandum of acknowledgement of oral family settlement, the promoters have decided that the company's real estate arm, Radhika Heights Ltd, would be managed by Ravinder Jain and may become a separate listed entity, Panacea Biotec said in a filing to the BSE.
Panacea Biotec has entered into a joint collaboration with Bion Pharma. In an interview to CNBC-TV18, Rajesh Jain, Joint MD of Panacea Biotech spoke about the latest happenings in his company and sector.
The seven abbreviated new drug applications are currently under development at Panacea Biotec, representing a total estimated market potential of more than USD 800 million.
The acquisition will help expand its footprint in Gurugram in northern India, Narayana Hrudayalaya said on Friday.
The company has entered into definitive agreement to divest its 100 percent stake held in NewRise Healthcare to Narayana Hrudayalaya.
Drug firm Panacea Biotec today announced launch of EasySix, a liquid hexavalent combination vaccine indicated for immunisation of newborn babies against common preventable diseases.
Tata Motors | Sun Pharma | DLF | Cadila Health | Jindal Steel | SpiceJet | Adani Enterprises | MOIL | Cox & Kings | HDIL | Liberty Shoes | Voltas | National Fertilisers | Ashiana Housing | Power Mech | Intellect Design Arena are stocks, which are in the news today.
The company Wednesday received the US Food and Drug Administration (USFDA) approval for an anti-migraine drug for which it had filed the Abbreviated New Drug Application (ANDA) in 2012.
The company has also received a notification from Pan American Health Organisation (PAHO) for purchase of Easyfive-TT vaccine in the event the agency should have any requirements through December, 31, 2019.
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Delta Corp, Panacea Bio, Vedanta, United Spirits, Cholamandalam Finance, Escorts, GSPL, Kaveri Seeds and Havells India.
Sudarshan Sukhani of s2analytics.com is of the view that NTPC, Tata Steel and Power Grid are excellent buying opportunities.